| ASSET | YEAR | % RETURN |
|---|---|---|
MaxLinear (MXL) | 2026 | 422.27% |
Ichor (ICHR) | 2026 | 411.83% |
Erasca (ERAS) | 2026 | 397.84% |
Anterix (ATEX) | 2026 | 382.51% |
Immunitybio (IBRX) | 2026 | 367.33% |
Ultra Clean (UCTT) | 2026 | 307.35% |
Veradermics (MANE) | 2026 | 281.59% |
Sellas Life Sciences (SLS) | 2026 | 236.63% |
Tango Therapeutics (TNGX) | 2026 | 232.88% |
Aehr Test Systems (AEHR) | 2026 | 232.83% |
Applied Opt (AAOI) | 2026 | 232.78% |
AXT (AXTI) | 2026 | 229.19% |
Definium Therapeutics (DFTX) | 2026 | 227.33% |
Enliven Therapeutics (ELVN) | 2026 | 221.42% |
P3 Health Partners (PIII) | 2026 | 221.19% |
Twist Bioscience (TWST) | 2026 | 212.76% |
Vishay Intertechnology (VSH) | 2026 | 211.94% |
Iridium Communications (IRDM) | 2026 | 209.64% |
Penguin Solutions (PENG) | 2026 | 209.21% |
BlackBerry (BB) | 2026 | 201.31% |
Sezzle (SEZL) | 2026 | 183.96% |
Oruka Therapeutics (ORKA) | 2026 | 181.13% |
Maase (MAAS) | 2026 | 178.33% |
Alumis (ALMS) | 2026 | 171.24% |
Spyre Therapeutics (SYRE) | 2026 | 164.44% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.